AZ's Lynparza Shines Again In Prostate Cancer Study
PARP Inhibitor Improves Overall Survival
Executive Summary
With a PDUFA date fast approaching, AstraZeneca has presented more data from the PROfound study, this time showing that Lynparza improved OS compared to hormonal therapies in men with advanced castration-resistant prostate cancer with BRCA1/2 or ATM mutations.
You may also be interested in...
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Clovis’s Rubraca Is First PARP For Prostate Cancer, But AZ’s Lynparza Coming Soon
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.